EFMH
KRYS icon

E Fund Management (HK)’s Krystal Biotech KRYS Stock Holding History

E Fund Management (HK)’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.6K Buy
77
+20
+35% +$5.98K 0.01% 246
2026
Q1 		$14.7K Buy
+57
New +$15.2K 0.01% 260

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

E Fund Management (HK)'s KRYS Position: Q2 2026 in Review

E Fund Management (HK) increased its Krystal Biotech (KRYS) stake by 35% in Q2 2026, buying an estimated $5.98K and bringing the position to 77 shares worth $28.6K. The position accounts for 0.01% of the portfolio, ranked #246.

E Fund Management (HK) first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • E Fund Management (HK) held 77 shares of Krystal Biotech worth $28.6K as of Q2 2026.
  • E Fund Management (HK) bought 20 Krystal Biotech shares in Q2 2026, an estimated $5.98K.
  • Krystal Biotech made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #246 holding.
  • E Fund Management (HK) first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.